beth israel deaconess medical center a harvard medical school teaching hospital

  • Contact BIDMC
  • Maps & Directions
  • Other Locations
  • Careers at BIDMC
  • Smaller Larger

Find a Doctor

Request an Appointment

Smaller Larger


Posted 8/13/2015

Posted in

  If you haven't heard about immunotherapy, the chances are good that you soon will. It is a growing and exciting area of research and some drugs treating cancer in a new way. The basic theory is that enhancing the immune system gives our bodies a chance to work better to destroy cancer cells.

Sometimes called biologic therapy, immunotherapy works in two ways: bolsters the immune system to make it more effective or giving the patient immune system components to make everything stronger. Some of these treatments make the whole immune system stronger and some stimulate it to only attack cancer cells. These new treatments are used to fight a number of different kinds of cancers, and it is likely they will become more common and more valuable in the future.

  Here is a good article from Cure Today about all of this:

Setting Off a Smart Bomb
Author: Arlene Weintraub

When Kevin Day was diagnosed with advanced renal cell carcinoma in the fall of 2011 at the age of 50, he was told he had just two years to live. His left kidney was removed, and he was put on Sutent (sunitinib) — the targeted drug that is a standard of care in stage 4 or recurrent renal cancer — but the disease had spread to his lungs and bones and there were no other good options to treat him.
Then Day’s doctor told him about a clinical trial of an immune-boosting drug called atezolizumab (MPDL3280A), which was opening up at the Carolina BioOncology Institute near his home in Charlotte, N.C. Day was accepted into the trial, and within two weeks of starting the drug, his tumors began to shrink. After eight weeks, they were half their original size. He was given the drug every three weeks for a year, by which time all of his tumors had disappeared.
In October of 2013, Day’s cancer relapsed in his spine, so he rejoined the study, which was testing atezolizumab as a single agent for various malignancies. Again, his cancer vanished. Day is still taking the drug as part of the ongoing study, and feeling lucky to be alive.
“The way I describe the drug is it boosts my immune system to fight the cancer,” Day says. “As long as it’s still working, I will stay on it. I can’t even put into words what this opportunity has meant to me.”
Checkpoint Inhibitors
Atezolizumab is among an emerging class of immunotherapy treatments called PD-L1 inhibitors. PD-L1 is a protein that is expressed on the surface of some cancer cells, enabling tumors to hide from T cells — important immune cells that have a natural ability to eradicate cancer. Inhibiting PD-L1 and
a related protein known as PD-1 effectively unveils cancer cells, taking the brakes off the immune system and unleashing the body’s innate ability to fight cancer.

Read more:


Add your comment